• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

JDRF wants to expand access to DIY diabetes tech – here’s how

October 25, 2017 By Sarah Faulkner

diabetesAs companies race to develop the first fully-automated insulin delivery system, a group of tech-savvy patients are hacking their own artificial pancreas systems. And industry is just starting to take notice of this highly motivated grassroots movement.

“They want more choice. They want more freedom. And, essentially, they want it now,” JDRF research director Dan Finan told Drug Delivery Business News.

But, as Finan pointed out, people making DIY diabetes technology end up using devices that aren’t regulated or secure. That’s where the JDRF’s latest initiative comes into play.

Last week the organization launched an effort to encourage device manufacturers to make devices that can communicate with one another. It’s just one part of a three-pronged approach to try to accelerate the development of automated insulin delivery systems, Finan said.

“What we want to do with this whole initiative is, while still supporting traditional development, in parallel bring this whole “We Are Not Waiting” movement up above the table, to where we can encourage the use of open and secure communication systems and also we can speed access of this excellent technology to the market,” he explained.

All it takes is one search of #WeAreNotWaiting on Twitter to find groups like Loop and NightScout – open-sourced projects that help people with diabetes reverse-engineer their own insulin delivery systems.

You’ll also find individual people working to hack into commercially available devices. Just yesterday, Twitter user @JBerian tweeted, “the quest is over. The 640g comms have been cracked,” apparently referring Medtronic‘s (NYSE:MDT) Minimed 640G system.

As part of its initiative, JDRF is offering a grant to device manufacturers that support open-protocol development.

“We want to encourage device manufacturers to open that up, use something that is openly published and certainly secure, like Bluetooth, which we’re all very accustomed to in this day and age, to make sure that the communication between all the different components that are going to be a part of this artificial pancreas device are communicating seamlessly and securely in order to bring this therapy to the patients,” Finan said.

The second part of JDRF’s initiative is to address a different hurdle with medical device manufacturers – liability.

“Everyone wants to help us realize our dream of an open-protocol ecosystem and not surprisingly, the only concern they have is how is liability going to be handled in this whole ecosystem,” Finan explained.

The private funding organization is also planning to open up dialogue with the FDA and other regulatory bodies to discuss the potential regulatory pathways available for these DIY devices.

“What we launching here in the form of this initiative is really just the effort, the drive to get the players together in a room. Hammer out the details, have the hard conversations, figure out what it is we need to do in order to make this open-protocol dream a reality,” Finan said. “We feel like we absolutely can get there, it’s just a matter of having the conversations with the players like the FDA, the heads of the companies. We’re going to hire some legal experts in terms of medical devices. We’re going to basically organize a round table community drive.”

So far, his initial conversations with device manufacturers have been positive, Finan noted. Most companies want to get their technology into as many hands as possible and that competitive drive is good for the overall patient community, he said.

“When things are competitive, it’s certainly excellent for the patient, and I think it also really opens up that competitive drive for the manufacturers,” Finan said. “Essentially the feedback was that, ‘Absolutely we want to play, and we want to get our products out there to as many people as possible – and we think our products is the best.'”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Juvenile Diabetes Research Foundation (JDRF), Medtronic

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS